Lantheus (NASDAQ:LNTH) Sets New 1-Year High – Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $103.89 and last traded at $103.00, with a volume of 2009265 shares changing hands. The stock had previously closed at $94.47.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on LNTH shares. Truist Financial reaffirmed a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 price target on shares of Lantheus in a research report on Thursday, May 7th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Finally, JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $99.71.

Lantheus Trading Up 9.0%

The stock has a market cap of $6.71 billion, a price-to-earnings ratio of 24.82 and a beta of -0.08. The business’s fifty day simple moving average is $83.21 and its 200 day simple moving average is $71.54. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.33 EPS for the current year.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. boosted its holdings in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares during the period. Western Wealth Management LLC acquired a new position in Lantheus in the first quarter worth $25,000. Smartleaf Asset Management LLC boosted its holdings in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC boosted its holdings in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new position in Lantheus in the second quarter worth $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.